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ReviewNF1 Tumor Suppressor Gene Function:
Narrowing the GAP
disease symptoms are not restricted to these tissues
(Table 1) (Riccardi, 1992; Upadhyaya and Cooper, 1998).
NF1 is a dominantly inherited genetic disease. Be-
Karen Cichowski*‡ and Tyler Jacks†‡
*Genetics Division
Department of Medicine
cause patients possess germline deletions or more sub-Brigham and Women’s Hospital and Harvard
tle loss-of-function mutations, the NF1 gene has beenMedical School
classified as a tumor suppressor (Cawthon et al., 1990;Boston, Massachusetts 02115
Viskochil et al., 1990; Wallace et al., 1990). Interestingly,†Department of Biology
while half of NF1 patients show a family history of theCenter for Cancer Research and Howard Hughes
disease, the remainder appear to have inherited de novoMedical Institute
mutations in the NF1 gene. Thus, the NF1 locus mayMassachusetts Institute of Technology
represent a mutational hotspot in the human genomeCambridge, Massachusetts 02139
(Hughes, 1994). Consistent with its role as a classical
tumor suppressor gene, loss of heterozygosity (LOH) or
Introduction “second-hit” somatic mutations in the inherited wild-
Tumor suppressor genes are typically identified through type allele have been detected in some tumor types in
their association with a familial cancer syndrome. As a NF1 patients (Xu et al., 1992; Legius et al., 1993; Shannon
result, information regarding the normal function of the et al., 1994; Colman et al., 1995; Sawada et al., 1996;
gene, especially the tissues in which gene function is Serra et al., 1997). However, as will be discussed below,
critical, can be inferred from the symptoms of the dis- simple haploidy for NF1 function may participate in the
ease. Such is the case for NF1, the gene responsible development of many NF1-related symptoms (a phe-
for neurofibromatosis type I. Patients with NF1 are pre- nomenon known as haploinsufficiency). An additional
disposed to developing a variety of benign and malig- complexity of the disease is its variable phenotypic ex-
nant tumors, many of which affect the peripheral and pression. Even siblings within the same family can ex-
central nervous systems (PNS and CNS). However, NF1 hibit a dramatically different range of symptoms, from
patients can also exhibit cognitive deficits and develop mild to severe. Thus, so-called modifier genes have
other symptoms unrelated to cancer, often affecting been proposed to play an important role in disease mani-
neural crest–derived tissues outside of the PNS, indicat- festation (Riccardi, 1992).
ing important growth control and developmental func- The NF1 gene was cloned in 1990 by the laboratories
tions in a wide range of cell and tissue types. Due to of Collins and White (Cawthon et al., 1990; Wallace et al.,
the prevalence of tumors and other symptoms affecting 1990). The encoded protein, neurofibromin, is expressed
the nervous system in NF1, this review will focus on ubiquitously, although its expression is highest in the
recent progress in understanding their development us- adult PNS and CNS (Upadhyaya and Cooper, 1998).
ing molecular genetic, genetic, biochemical, and cell Neurofibromin shares a region of similarity with the cata-
biological approaches. By considering the findings from lytic domains of the mammalian p120RasGAP protein
each of these approaches, an integrated picture regard- and an extended similarity with the Saccharomyces cer-
ing the normal function of NF1 is beginning to emerge. evisiae Ras-GAP proteins IRA1 and IRA2 (Figure 1) (Bal-
lester et al., 1990; Xu et al., 1990b). GAP proteins, or
GTPase-activating proteins, function to inhibit low mo-The Disease, the Gene, and the Protein
lecular weight G proteins such as Ras by stimulatingNF1, first described by Fredrich von Recklinghausen in
their intrinsic GTPase activity (Figure 2). Indeed, neurofi-
1882, is a common familial tumor predisposition syn-
bromin has been shown to function as a GAP for Ras
drome affecting 1 in 3500 individuals worldwide (Ric-
in vitro and in vivo (Martin et al., 1990; Xu et al., 1990a).
cardi, 1992). The primary clinical feature of the disease Furthermore, many NF1-deficient tumors exhibit ele-
is the development of benign peripheral nerve sheath vated levels of Ras-GTP, supporting the notion that un-
tumors, termed neurofibromas. In a small percentage regulated Ras signaling may contribute to their develop-
of NF1 patients, a particular type of neurofibroma (plexi- ment (Basu et al., 1992; DeClue et al., 1992; Bollag et
form, see below) progress to malignant peripheral nerve al., 1996; Guha et al., 1996). The consequences of Ras
sheath tumors (MPNSTs). NF1 patients are also predis- activation are well described, and mutations or amplifi-
posed to astrocytic brain tumors, pheochromocytoma cations of many genes in the Ras pathway have been
and myeloid leukemia (Bader, 1986; Riccardi, 1992). detected in a variety of human tumors (Figure 2). In
Noncancerous symptoms of the disease can include some NF1-deficient cells and tumors, the inappropriate
intellectual deficits, bone deformations, benign lesions activation of these downstream effectors has also been
of the iris (Lisch nodules), and hyperpigmentation de- reported (Mahgoub et al., 1999; Hiatt et al., 2000; Ingram
fects of the skin known as cafe´-au-lait macules. Because et al., 2000; Lau et al., 2000). However, an important
many of the cardinal features of the disease affect neural goal in the field has been to determine whether Ras
crest–derived tissues, NF1 has been described as a neu- regulation is the primary and/or only function of neurofi-
rocristopathy. However, as illustrated by this partial list, bromin, in part because such information might guide
the development of therapies for NF1-deficient tumors.
The observation that the mutational inactivation of a‡ E-mail: kcichowski@rics.bwh.harvard.edu (K. C.); tjacks@mit.edu
(T. J.). Ras-GAP protein may exert such pleotropic effects has
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Table 1. Partial List of NF1 Symptoms
Symptom Cell type(s) implicated Developmental origin
Neurofibromas/MPNSTs Schwann cells, Neural crest
Perineurial cells, Mesoderm
Fibroblasts, Mesoderm
PNS neurons Neural crest
Cafe-au-lait macules Melanocytes, Neural crest
Keratinocytes Mesoderm
Lisch nodules (Iris) Melanocytic cells Neural crest
Cognitive deficits CNS Neurons, Neural tube
Other? ?
Long bone dysplasia ? Mesoderm
Craniofacial dysplasia ? Neural crest
Pheochromocytomas Chromaffin cells of the adrenal medulla Neural crest
Myeloid leukemia Myeloid cells Mesoderm
Glioblastoma Astrocytes Neural tube
intriguing biological implications. While the Ras pathway major effort has been to dissect the genetic events that
underlie different aspects of disease development. De-has been extensively studied in the context of tumori-
genesis and in several cell signaling pathways, the nor- termining when and in what cell types somatic inactiva-
tion of the normal NF1 allele actually occur is critical formal consequences of regulated Ras activation have
been more difficult to examine, especially at an organis- understanding the basic pathology of any phenotype
and is ultimately necessary for elucidating the normalmal level. Numerous studies have suggested that the
appropriate level or duration of Ras activity is required function of the gene. This exercise has proven to be
surprisingly difficult for many NF1-related symptoms, infor eliciting a specific proliferative or differentiative re-
sponse. For example, in the pheochromocytoma-derived part because of the complex interactions of cell types
in the PNS and CNS. A second major goal has been toPC12 cell line, signals that lead to a transient activation
of the Ras-ERK pathway result in proliferation, while dissect NF1 function on a cellular and biochemical level,
primarily utilizing isolated cell types that have been im-more robust and/or sustained activation of this pathway
induce differentiation (Marshall, 1995; Schlessinger, 2000). plicated in disease development. Finally, in part to assist
the aims of these first two goals, animal models recapitu-Furthermore, while overexpression of activated Ras is
typically associated with transformation, in some pri- lating various disease symptoms have been generated.
mary cells it has been shown to induce senescence or
growth arrest (Ridley et al., 1988; Serrano et al., 1997). NF1 and Peripheral Nerve Sheath Tumors
Dermal NeurofibromasThe observation that NF1 patients exhibit a variety of
tumorigenic and developmental symptoms underscores The most common, and perhaps the most complex,
feature of NF1 is the development of benign neurofibro-the importance of this fine-tuned regulation of the Ras
pathway. Thus, investigating neurofibromin function will mas. The peripheral nerve sheath normally provides
structural and metabolic support to nerves and, in thenot only yield critical information about this devastating
human disease but should also lead to a broader under- case of myelinated fibers, potentiates the conduction
of action potentials. The most common tumors can arisestanding of the biological consequences and impor-
tance of appropriate Ras attenuation. from small nerve radicals or larger nerve branches and
grow as discrete lesions in the dermis or epidermis rang-In an attempt to understand NF1 function in a biologi-
cal context, several approaches have been taken. One ing from 0.1 to several centimeters in diameter (collec-
Figure 1. Sequence Similarity among Ras-
GAP Proteins
Similarity of neurofibromin with the mamma-
lian p120 RasGAP and yeast RasGAP pro-
teins IRA1 and IRA2. Note the similarity with
IRA proteins extending beyond the catalytic
GAP-related domain (GRD). Src-homology 2
(SH2), Src-homology 3 (SH3), and pleckstrin




Figure 2. Neurofibromin Functions as a
Ras-GAP
(A) RasGAP proteins such as neurofibromin
inactivate Ras by catalyzing the hydrolysis
of Ras-GTP to Ras-GDP. Exchange factors
activate Ras by potentiating the exchange of
GDP for GTP.
(B) Simplified version of the Ras pathway.
Genes encoding highlighted proteins have
been found to be mutated or amplified in hu-
man cancer (blue).
tively called dermal neurofibromas). While these tumors most easily observed during development and wounding.
During development, the migration, proliferation, sur-are benign, patients can develop thousands of them
which, depending on location, can be painful and disfig- vival, growth arrest, and differentiation of each of these
cell types is dependent on cues from surrounding cellsuring. One of the unusual features of neurofibromas is
their cellular heterogeneity. Electron micrographic (EM) (Jessen and Mirsky, 1998). In many respects, regenera-
tion following injury recapitulates this developmentaland histological analysis have revealed the presence of
multiple cell types, including Schwann cells, neurons, process, and illustrates the plastic properties of these
cells in the peripheral nervous system (Kioussi andperineurial cells, fibroblasts, and mast cells, among oth-
ers (Riccardi, 1992). However, the primary component Gruss, 1996).
Neurofibromas contain all of the cell types found inof these tumors is intensely debated (Fialkow et al.,
1971; Skuse et al., 1991). Some studies report that normal peripheral nerve. In addition to an inappropriate
number of all cell types, Schwann cells are found disso-Schwann cells comprise 40%–80% of the tumor mass,
while others report that perineurial cells or fibroblasts ciated from nerves and the perineurium is disrupted
(Figure 3). However, the interdependency of these cellmay be the more prevalent component(s) (Peltonen et
al., 1988; Erlandson, 1991). A consensus is further com- types has severely hampered the definitive elucidation
of the etiology of these lesions. For example, does theplicated by the variability of the cellular composition
among tumors and regionally within the same tumor. initial cellular defect result in the hyperproliferation of
one cell type (Schwann cells, perineurial cells, or fibro-Plexiform Neurofibromas
In contrast to dermal neurofibromas, which are typically blasts) or many? Alternatively, does the initiating signal
(from any cell type, including neurons and mast cells)small, plexiform neurofibromas can develop internally
along the plexus of major peripheral nerves and become result in an increase in growth factor production, or a
decrease in an inhibitory factor, causing a local prolifera-quite large, involving an entire limb or body region
(Upadhyaya and Cooper, 1998). While these tumors are tive response? Could neurofibromas develop as a result
of both paracrine and cell-autonomous defects? Finally,also benign, they can be debilitating and can progress
to malignancy. The cellular make-up of these lesions is what is the initial trigger: a second hit mutation, a spe-
cific environmental event, or another mechanism? Thegenerally similar to dermal lesions. However, as dis-
cussed below, the timing of their development as well answers to these and related questions have been elu-
sive for decades and are only now becoming clarified.as their growth properties may indicate differences in
the mechanism of tumor initiation. The following section will focus on insights gained from
human genetic studies and animal models as well asThe Normal Nerve and Tumor Development
The inherent interdependency of the cell types present questions that remain for the future.
in normal peripheral nerves underlies the complexity of
neurofibromas (Bennington, 1978) (Figure 3). In a non- Are Second-Hit Mutations Required
for Tumor Development?pathological state, a single peripheral nerve fiber is as-
sociated with a myelinating or nonmyelinating Schwann NF1 was first suggested to be a tumor suppressor gene
because a high percentage of inherited mutations werecell. Several nerve fibers and associated Schwann cells
are clustered into a nerve bundle (or fascicle) and each predicted to result in an inactive (or absent) protein prod-
uct. Accordingly, based on Knudson’s two-hit hypothe-fascicle is surrounded by concentric layers of perineurial
cells. These specialized cells form tight junctions and sis, one would predict that a second mutation in the
inherited wild-type allele would initiate tumor develop-are the primary component of the perineurium, which is
thought to serve as a diffusion barrier to macromole- ment (Knudson, 1971). Indeed, LOH or second-hit muta-
tions were readily detected in pheochromocytomas, my-cules. Multiple nerve fascicles, bound by loose connec-
tive tissue, constitute an individual nerve. In addition to eloid leukemias, and MPNSTs from NF1 patients (Xu
et al., 1992; Legius et al., 1993; Shannon et al., 1994).the cell types mentioned, fibroblasts, endothelial cells,
and occasional mast cells are present in a normal nerve Furthermore, studies examining mice carrying a tar-
geted disruption of one Nf1 allele confirmed its functionfascicle. The reciprocal signaling among these cells is
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remains possible that such mutations may not be strictly
necessary for benign tumor development. Moreover, the
genotype of the “normal” cells in the tumor (NF11/2) may
also be a contributing factor in tumorigenesis, with these
cells possibly exhibiting haploinsufficiency for NF1 func-
tion (see below).
Although Nf11/2 mice were shown to be cancer prone
and provide strong evidence for the tumor suppressor
properties of the Nf1 gene, these animals did not de-
velop neurofibromas. The observation that mice de-
signed to model a human disease do not manifest all
of the disease symptoms is not uncommon. In some
cases, the compensatory functions of related proteins
are likely to underlie species-specific differences (e.g.,
Rb1/2 mice [Mulligan and Jacks, 1998]). In others, the
frequency of somatic mutations has been proposed to
be a rate-limiting event in mice (e.g., Apc1/2 mice)
(Luongo et al., 1994). Because embryos homozygous
for an Nf1 mutation die in midgestation (see below)
(Brannan et al., 1994; Jacks et al., 1994), the question
of second-hit mutations in neurofibroma development
was addressed experimentally through the creation of
chimeric mice partially composed of Nf12/2 cells (Ci-
chowski et al., 1999). This was achieved by generating
Nf1-deficient ES cells and injecting them into wild-type
blastocysts. Strikingly, nearly all of the resulting chimeric
animals developed numerous neurofibromas. Histologi-
cal and EM analysis confirmed the similarity of these
Figure 3. Normal Peripheral Nerve and Model of Neurofibroma De- lesions to human plexiform tumors. Unlike NF1 patients,
velopment however, these animals did not develop dermal lesions.
(A) Peripheral nerves are comprised of multiple cell types; neurons This may indicate additional species-specific differ-
(blue), Schwann cells (red), perineurial cells (gray) and fibroblasts ences in mice versus humans and/or may suggest a
(yellow). Occasional mast cells are also observed (green).
different developmental mechanism underlying dermal(B) Neurofibromas exhibit an increased number of all cell types. In
neurofibroma development. Regardless, this studyaddition, Schwann cells are often dissociated from neurons and the
demonstrated that complete loss of Nf1 is an obligateperineurium is disrupted.
(C) Neurofibroma development may be initiated by mutation or loss step in the development of benign plexiform neurofibro-
of the inherited wild-type NF1 allele in Schwann cells (pink cells are mas in mice. Taken together with data demonstrating
NF12/2 ). This may trigger tumor development by initiating a cascade somatic NF1 mutations in human tumors, these results
of changes in other cell types as a result of their interdependency
support the view that second-hit mutations play a keyand/or haploinsufficiency. Wounding and hormonal exposure may
role in the development of human lesions as well.also promote development.
Which Cell Type Initiates
Neurofibroma Development?as a tumor suppressor gene. Nf11/2 mice are tumor
prone and develop two of the malignancies associated For a number of years, Schwann cells have been consid-
ered to be the initiating cell type in neurofibroma forma-with NF1: pheochromocytoma and myeloid leukemia
(Jacks et al., 1994). In both tumor types, loss of the wild- tion, i.e., the cell type that incurs a somatic mutation.
First, Schwann cells are a major cellular component oftype allele has been observed at high frequency.
The requirement for second-hit mutations in the devel- these tumors, although perineurial cells and fibroblasts
may also be highly represented. Second, MPNSTs,opment of benign neurofibromas has been controver-
sial. Early work in this area concluded that such muta- which are thought to arise from a subset of neurofibro-
mas, express Schwann cell markers. Finally, and mosttions were not present in this tumor type. However, more
recently, investigators have reported second-hit muta- persuasively, LOH at the NF1 locus has been reported in
Schwann cells from neurofibromas (Kluwe et al., 1999a;tions or LOH in human neurofibromas, albeit at low fre-
quency (Colman et al., 1995; Sawada et al., 1996; Serra Serra et al., 2000). These observations are also consis-
tent with the possibility that the somatic mutationalet al., 1997; Jessen and Mirsky, 1998; Kluwe et al., 1999b;
Rasmussen et al., 2000). The difficulty in detecting these event is involved in the eventual progression to malig-
nancy. However, it is important to note that while dermalmutations may be due to the heterogeneity of cell types
in the tumor samples (not all of which would have been neurofibromas never progress to malignancy, second-
hit mutations in the NF1 locus have been detected, fur-predicted to have undergone a mutational event) and/
or the large size of the gene (335 kb genomic, 9 kb ther supporting the notion that loss of NF1 function
is required (in at least one cell type) for benign tumorcoding) making the detection of subtle mutations chal-
lenging. Importantly, while the recent data demonstrate formation.
The Nf12/2 chimeric animals described above also didthat second-hit mutations can occur in neurofibromas, it
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not help to resolve the issue of identifying the initiating proliferative response. However, there appears to be
some additional complications in this system. Curiously,cell type. In the subset of chimeric animals that were
while Nf1-deficient cells hyperproliferate in response togenerated with ES cells carrying a b-galactosidase ex-
forskolin, proliferation is diminished in response to GGFpressing transgene, the majority of cells within neurofi-
and serum in comparison to wild-type cells. Notably,bromas were found to be derived from the Nf1-deficient
rat Schwann cells overexpressing v-Ras exhibit similarES cells. Because this observation may be related to
proliferative defects. At first glance, this appears to con-the limitations of chimeric analysis, developing a more
tradict a role for Ras as a positive growth signal. How-refined animal model may be a powerful way of resolving
ever, given that Ras has previously been shown to playthis issue. If loss of Nf1 in Schwann cells triggers neurofi-
dual roles in other systems, these observations suggestbroma development, then a conditional inactivation of
that Schwann cells may be sensitive to the level and/orNf1 in Schwann cells (or their precursors) should pro-
duration of Ras activity and that a moderate level ofmote tumor development. Parada and colleagues have
Ras activation may promote Schwann cell proliferation.constructed a conditional mutant Nf1 allele in mice to
Moreover, it suggests that the loss of Nf1 in Schwannaddress these and related issues (L. Parada, personal
cells (and other cell types) may have different effectscommunication).
depending on the cell’s microenvironment. Regardless,
these studies have clearly demonstrated that multipleCellular Studies
cellular properties of Schwann cells are altered in a cell-In addition to human genetic and mouse modeling ap-
autonomous manner following loss of Nf1 function.proaches, cell culture studies of the cell types that con-
Perineurial Cells and Fibroblastsstitute these and other cancers associated with NF1
Perineurial cells are thought to arise from a mesodermalhave been highly informative. Cells derived from NF1
origin rather than from the neural crest. In fact, embry-patients as well as primary cells from mutant mice have
onic fibroblasts can be induced to differentiate into thisbeen particularly useful in this endeavor. With respect
specialized cell type in neuronal/Schwann cell cocultureto neurofibroma development, one of the goals has been
systems (Bunge et al., 1989). Importantly, perineurialto try to identify specific cell-autonomous defects, thus
cells can be distinguished from fibroblasts by ultrastruc-establishing the cell types in which NF1 function is criti-
tural and immunohistochemical markers. To examinecal. Given the complexity of these lesions, it is not sur-
the cellular behavior of Nf12/2 perineurial cells, Rosen-prising that NF1 has been shown to function in all of the
baum and colleagues utilized an in vitro coculture assaycell types that comprise neurofibromas; Schwann cells,
(Rosenbaum et al., 1995). When mouse embryonic fibro-neurons, perineurial cells, fibroblasts, and mast cells.
blasts (MEFs) were cocultured with wild-type rat neuron/These observations further support the possibility that
Schwann cell cultures, both wild-type and Nf1-deficientwhile defects in one cell type might initiate tumorigene-
cells were able to differentiate into cells exhibiting peri-sis, multiple cell types may contribute to their devel-
neurial cell features. However, Nf1-deficient perineurialopment.
cells were unable to form fascicles around nerve bundlesSchwann Cells
and appeared to be more abundant, with defects remi-
To investigate the function of NF1 in Schwann cells
niscent of those observed in neurofibromas. Nf1-defi-
independent of other changes that may have occurred
cient MEFS alone also appeared to exhibit proliferative
during tumorigenesis, investigators have compared the
defects, although these defects were not extensively
cellular phenotype of primary Nf12/2 and wild-type mu- characterized. Thus, Nf12/2 perinereurial cells and fibro-
rine Schwann cells. Interestingly, like Schwann cells de- blasts also appear to exhibit some cell-autonomous de-
rived from human neurofibromas, Nf12/2 murine Schwann fects. Cellular abnormalities in perineurial cells and fi-
cells exhibit increased angiogenic and invasive proper- broblasts from human neurofibromas have also been
ties compared to wild-type cells (Sheela et al., 1990; reported, suggesting that the biology of these cells is
Kim et al., 1997b). Cells heterozygous for the mutant also altered in some way in human tumors (Peltonen et
allele exhibited similar properties, indicating that loss al., 1988; Woodruff, 1996).
of one allele is sufficient to confer these properties. Neurons
Importantly, proliferative defects were also observed in Finally, Nf1-deficient primary neurons have also been
these cells (Kim et al., 1997b). Kim et al. found that Nf1- shown to possess striking defects in vitro. Vogel and
deficient cells hyperproliferated in response to forskolin, colleagues have demonstrated that Nf1-deficient neural
an activator of adenylyl cyclase, in the absence of serum crest– and placode–derived sensory neurons can de-
or exogenous growth factors. While cAMP is a second velop, extend neurites, and survive in the absence of
messenger known to potentiate the proliferative re- neurotrophins (Vogel et al., 1995). Furthermore, the en-
sponse of Schwann cells to growth factors, such as glial hanced survival of Nf1-deficient sensory neurons is de-
growth factor (GGF), it is normally unable to do so alone pendent on the Ras-PI3 kinase pathway (Klesse and
in most culture systems (Kim et al., 1997a). Thus, one Parada, 1998). Again, this observation is consistent with
interpretation of these results is that loss of Nf1 provides a role for neurofibromin as a Ras-GAP in these cells; as
a signal that is able to cooperate with cAMP to induce it would be predicted that loss of Nf1 would result in
proliferation. It appears that the absence of the Ras- the inappropriate activation of Ras and its downstream
GAP activity of neurofibromin is at least partially respon- effectors, including PI3 kinase and Akt (proteins known
sible for this effect, as Ras-GTP levels are elevated in to function in survival pathways in neurons and other
these cells. Furthermore, a small molecule inhibitor of cell types). Although constitutive Ras and PI3 kinase
farnesyltransferase (FTI), an enzyme that is essential for activation were not formally demonstrated in this study,
elevated ERK activity was noted. At this time, it is uncleartargeting Ras to the plasma membrane, reduced the
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if or how this cellular defect may participate in neurofi- tein (MBP) promoter, induces neurofibroma develop-
ment in mice (Jensen et al., 1993; Mazarakis et al., 1996).broma development or whether the requirement for Nf1
The SV40 Lg T gene is a potent transforming agentin neurons may explain other features of the disease.
that mediates its effects by inhibiting tumor suppressorHowever, these observations may explain the overabun-
proteins such as p53 and pRB (Weinberg, 1991). Whiledance of neural crest–derived neurons of sympathetic
a direct or indirect connection with NF1 remains to beganglia in Nf12/2 embryos reported by Brannan et al.
established, NGF and MBP are normally expressed by(1994).
Schwann cells, further implicating this cell type in neuro-
fibroma development. Furthermore, NGF expressionAre Plexiform Neurofibromas
precedes MBP expression by several days in mouseDevelopmental Tumors?
glial cells (Kioussi and Gruss, 1996). Of course, otherA particularly interesting feature of neurofibroma devel-
explanations could account for the different tumor spec-opment is the disparity among tumors. Nearly all NF1
tra including genetic background and level of transgenepatients eventually develop neurofibromas, although the
expression. However, these observations are consistentnumber of tumors can range from a few to thousands
with the hypothesis that disruption of cell growth controlper patient. The most common lesions are dermal neuro-
must occur at an early, specific, developmental stage tofibromas, which develop progressively starting in the
promote neurofibroma development. Given that humansecond decade of life. These lesions are typically small,
plexiform neurofibromas can grow to a much larger size,but patients can develop many. In contrast, plexiform
and that malignant tumors exclusively arise from thisneurofibromas are less common, affecting approxi-
subset of benign lesions, understanding the mecha-mately one-quarter of patients. They are typically much
nisms underlying their development is of considerablelarger, and can encompass entire nerve branches. In
clinical importance. Identifying the specific develop-contrast to the delayed development of dermal neurofi-
mental time point at which a second-hit NF1 mutationbromas, plexiform lesions are thought to be congenital
is required may be critical in this effort.(Riccardi, 1992). Patients can overtly manifest these tu-
mors during early childhood. In addition, even if a tumor
Other Events That May Contributeis not apparent, overlying pigmented patches of skin
to Tumor Developmentand differential hair patterning are often indicative of an
In addition to second-hit mutations, nongenetic eventsunderlying lesion. Riccardi has suggested that the latter
such as local trauma and hormonal changes have beenobservation is an indication that a defect has been initi-
implicated in the development of neurofibromas in NF1ated in utero, as hair patterns are established by 16
patients (Riccardi, 1992). Sites of injury have been anec-weeks of development. In addition to the likely develop-
dotally associated with the progressive appearance ormental origin of these tumors, plexiform lesions exclu-
increased growth of neurofibromas, although a formalsively give rise to malignant tumors (Woodruff, 1996).
study has not been reported. As a result it has beenThese fundamental differences between dermal and
suggested that defects in processes that regulateplexiform neurofibromas suggest that the timing of so-
wound healing and/or nerve regeneration may be in-matic NF1 mutations may determine the clinical course
volved in triggering neurofibroma development. In part,
of the tumor, with early mutations promoting more ag-
the increased number of mast cells present at sites of
gressive tumor development and a propensity for malig-
injury, which may secrete growth promoting factors, has
nant progression. been proposed to contribute to their development. Im-
Several findings support the possibility that develop- portantly, defects in mast cells, and fibroblasts during
mental second-hit mutations in the Nf1 gene cause wound healing, have been observed in Nf11/2 mice (Atit
plexiform neurofibromas. First, when considering the et al., 1999; Ingram et al., 2000). Therefore, it has been
development of plexiform-type neurofibroma develop- suggested that wounding, compounded by NF1 haploin-
ment in Nf12/2 chimeric mice, it is important to note sufficiency in several responding cell types, may initiate
that these animals are generated by introducing Nf1- and/or potentiate neurofibroma development. Notably,
deficient cells into an early stage embryo (E 3.5). There- inflammatory cells and other cell types comprising the
fore, in this system, Nf1-deficient cells are present tumor microenvironment have recently been proposed
essentially throughout development. Perhaps Nf11/2 to play a more active role in tumor development in other
animals do not develop these tumors due to a reduced systems. (Coussens et al., 2000; Hanahan and Wein-
mutational rate of the Nf1 gene in mice, as compared berg, 2000).
to humans, which is compounded by the requirement In addition to wounding, hormonal changes have been
for a restricted developmental window in the target cell proposed to participate in neurofibroma development.
population. One could address this question more defin- First, neurofibromas are often initially detected at the
itively by timing the use of an inducible and/or de- onset of puberty. Second an increase in number or size
velopmentally regulated targeted disruption of Nf1 in of neurofibromas has been associated with pregnancy,
mice. Second, in addition to the chimeric mouse model, although the increased size is apparently transient and
prenatal exposure to ENU has been shown to cause neurofibromas become smaller after giving birth. (Ric-
neurofibroma development in rats (Cardesa et al., 1989). cardi, 1992). The potential mechanisms underlying these
Importantly, the timing of exposure appears to be criti- observations are unknown and have not been tested in
cal—plexiform tumors were only observed in animals any animal models to date.
treated at E15 and not in animals treated at later devel-
opmental time points. Finally, transgenic expression of A Model of Neurofibroma Development
the SV40 large (Lg) T oncoprotein from the nerve growth Considering the data from genetic analysis, case reports
of NF1 patients, and animal studies, unifying models offactor (NGF) promotor, but not from a myelin basic pro-
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neurofibroma development can be formulated (Figure subset of those cases, LOH at the INK4 locus was de-
tected (Berner et al., 1999; Kourea et al., 1999; Nielsen3). With respect to plexiform lesions, data from NF pa-
tients and animal models support the hypothesis that et al., 1999). p16INK4a is a cyclin-dependent kinase
inhibitor affecting cyclin D/cdk 4 complexes, whilesecond-hit mutations trigger tumor development and
that this event is likely to occur during gestation. Cur- p14ARF activates the p53 pathway (Sherr, 1998). Thus,
the observation that MPNSTs may also develop as arently, most data suggest that Schwann cells are the
initiating cell type, although this is not formally proven. result of p53 mutations may imply that inactivation of
p14ARF rather than p16INK4a is more important in theRegardless, while a second-hit mutational event is likely
to play a role in tumor initiation, the majority of cells progression to malignancy.
A more definitive causal role for p53 mutations inwithin the tumors, which are represented by multiple
different cell types, do not harbor these second-hit mu- MPNSTs has been recently suggested by analyzing
mouse strains carrying mutations in both the Nf1 andtations, and remain NF11/2 . Notably, however, Schwann
cells, perineurial cells, mast cells, and fibroblasts exhibit p53 tumor suppressor genes (Cichowski et al., 1999;
Vogel et al., 1999). The mouse Nf1 and p53 genes areevidence of haploinsufficiency in in vitro systems (neu-
rons have not been reported). Perhaps these cells play closely linked on chromosome 11 in mice (they are both
on chromosome 17 in humans but on opposite arms).an active role in tumor development due to their in-
creased sensitivity to and/or release of growth factors Therefore, mice carrying mutations on opposite chromo-
somes (NP trans) versus mice carrying mutations on thein the developing lesion. A Schwann cell may undergo
a second-hit mutation and affect surrounding perineurial same chromosome (NP cis) were generated and aged.
Two groups demonstrated that NP cis mutant mice de-cells, Schwann cells, fibroblasts, and neurons. Affected
perineurial cells may promote the development of these veloped MPNSTs at high frequency. In both cases, LOH
at both the Nf1 and p53 loci were detected. Given thatlesions in two ways: hyperproliferation and disruption of
the perineurium. The breakdown of this diffusion barrier loss of an entire chromosome is thought to be the most
common mutational mechanism in the mouse, LOH wasmay further potentiate tumor development due to the
inappropriate exposure of internal cells to circulating presumed to occur as a result of such an event. Con-
versely, while Nf1 and p53 mutations cooperated in tu-growth factors, hormones, or acutely at the site of
trauma. mor development in the trans mice, these animals did
not develop MPNSTs, but rather developed tumors simi-Second-hit mutations have also been detected in der-
mal neurofibromas, and may initiate their development lar to those observed in the Nf11/2 or p531/2 parental
animals. As was predicted, loss of the wild-type Nf1 oras well. However, because these tumors do not appear
until later in life, they may arise as a result of a mutation p53 allele (but not both) was observed in these tumors,
most likely due to the mutational mechanism describedthat occurs during adolescence or early adulthood. Al-
ternatively, some believe that second-hit mutations are above. Taken together, these results suggest that null
mutations in Nf1 and p53 cooperate in the developmentnot required for the development of dermal tumors and
that nongenetic events are more important in the gene- of MPNSTs.
In addition to genetic alterations detected in MPNSTs,sis of these lesions. This opinion is predicated on the
observation that some patients can develop thousands DeClue and colleagues have also observed an increase
in EGF-receptor (EGF-R) expression in Schwann cellsof dermal neurofibromas. While the NF1 locus does ap-
pear to exhibit a high mutational frequency, it is difficult from these lesions (DeClue et al., 2000). Normal human
Schwann cells associated with neurons do not typicallyto predict whether the frequency is high enough to drive
the development of so many tumors in some patients. express this receptor and instead express other mem-
bers of the EGF-R family, Erb2, and -3, which bind GGF.Thus, the mechanism underlying the development of
these lesions may be even more complex. However, These investigators found that a high, but varying, per-
centage of Schwann cells within human MPNSTs ex-regardless of the precise mechanism or the tumor sub-
type, the fact that the majority of cells within these le- pressed EGF-R. Schwann cells in benign neurofibromas
rarely expressed EGF-R, implying that upregulation ofsions do not harbor a second mutated allele suggests
that therapies aimed at potentiating neurofibromin func- this receptor may play an important role in the progres-
sion to malignancy. Cell lines derived from malignanttion, and thus attempting to correct the state of haploin-
sufficiency, may be useful. tumors, as well as transformed Nf12/2 mouse Schwann
cells, similarly expressed EGF-R and were responsive
to EGF in vitro. Importantly, the proliferation of culturedThe Progression to Malignancy
Schwann cells from human tumors (and the transformedBecause focal regions of malignancy can be detected
mouse cells) was inhibited by an EGF-R antagonist. Atin large benign lesions, MPNSTs are thought to develop
this point, it is unclear if EGF-R expression precedes orfrom neurofibromas (Woodruff, 1996). Progression to
follows a second mutational event such as a p53 ormalignancy occurs at a relatively low frequency (5%
INK4 mutation. Regardless, these studies suggest theof NF1 patients develop MPNSTs) and only occurs in
possible therapeutic utility of EGF-R antagonists.plexiform tumors. p53 mutations and chromosome 17p
deletions (the chromosomal region in which p53 resides)
have been detected in malignant tumors and in many Gliomas/Astrocytomas
While defects in glial cells in the PNS (Schwann cells)cases LOH or second-hit mutations in the p53 gene have
also been reported (Menon et al., 1990; Greenblatt et underlie neurofibroma development, NF1 patients are
also predisposed to developing gliomas, tumors derivedal., 1994). Mutations in the INK4 locus, which inactivate
both the p16INK4a and p14ARF tumor suppressor from glial cells in the CNS (astrocytomas). Tumors can
develop in all regions of the brain in these patients;genes, have also been identified in MPNSTs and, in a
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however, they most commonly affect the optic pathway usual bright objects) in the brain. These lesions have
been proposed to represent areas of dysplastic glial(pilocytic astrocytomas), brainstem, and cerebellum.
Between 15% and 50% of NF patients develop some proliferation and aberrant myelination. UBOs have been
suggested by some to underlie cognitive impairment,type of glioma, although they are often indolent in nature
(Upadhyaya and Cooper, 1998). Hence, visual distur- although this point is highly debated. Learning disabili-
ties may be secondary to abnormal brain development.bances and neurological deficits are the most common
complications. While LOH at the NF1 locus has not been The most informative data regarding the etiology of
learning defects associated with NF1 mutations maydetected, an absence of the protein and elevated Ras-
GTP levels have been observed, suggesting that loss of be from studies examining the effects of mutations in
Drosophila. Loss of NF1 results in various phenotypesneurofibromin function contributes to the development
of these lesions (Lau et al., 2000). in flies (see below) (Guo et al., 1997, 2000; The et al.,
1997). In particular, Guo et al. demonstrated that NF1NF1 is normally expressed at relatively low levels in
astrocytes. However, Giordano and colleagues have re- mutant flies exhibit learning and short-term memory de-
fects that are independent of developmental effects.ported that NF1 is dramatically upregulated in response
to cAMP and proinflamatory cytokines in astrocytes in These results support the hypothesis that NF1 is re-
quired for normal neuronal function in flies. Interestingly,vitro, and in response to ischemia in vivo in a rat model
system (Giordano et al., 1996). These observations have these studies also implicate a defect other than Ras
regulation in these phenotypes (see below).led to the speculation that in response to injury or ische-
mia, neurofibromin may normally act as a growth inhibi- Nf11/2 mice also appear to recapitulate some learning
disabilities associated with NF1 (Silva et al., 1997). Silvator and/or promote astrocyte differentiation. However,
in the absence of neurofibromin, these signals may lead and colleagues have found that these mice exhibit dis-
rupted spatial learning and contextual discrimination. Asto proliferation, and in this way may participate in tumor
development. Thus, an inappropriate response to injury in humans, these phenotypes were variably expressed.
Further studies utilizing these mice, as well as flies,has been speculated to play a role in NF1-related glial
tumors in both the CNS (astrocytomas) and PNS (neuro- should help further dissect the mechanism underlying
learning disabilities associated with the human disease.fibromas). Interestingly, there also appears to be an ef-
fect of haploinsufficiency on astrocyte proliferation;
Nf11/2 astrocytes exhibit proliferative defects in vitro NF1 Function in Neural Crest–Derived Tissues
and an increased number of astrocytes in the brains of Many NF1-associated symptoms suggest a general role
NF1 patients as well as Nf11/2 mice have been observed for neurofibromin in neural crest–derived tissues (Upad-
(Nordlund, 1995; Gutmann et al., 1999). However, it is hyaya and Cooper, 1998). Two of the cell types that
not yet clear that these defects are completely cell au- comprise neurofibromas, Schwann cells and peripheral
tonomous. Given that astrocytes can respond to signals neurons, are derived from the neural crest. Similarly,
from neurons, and that NF1 mutations would be present pheochromocytomas, which arise from the chromaffin
in neurons as well as astrocytes, it is possible that the cells of the adrenal medulla in NF1 patients, are also
increased number of astrocytes in NF1 patients and neural crest–derived. Skin hyperpigmentation in NF1 pa-
heterozygous mice may be due to or compounded by tients has also been attributed to defects in neural crest–
defects in neurons. Interestingly, mice carrying a neu- derived melanocytes, although keratinocytes (or abnor-
ronal-specific targeted disruption of the Nf1 gene also mal interactions between these two cell types) may also
exhibit an increase in astrocytes in the brain, supporting play a role in their development (Upadhyaya and Cooper,
this possibility (L. Parada., personal communication). 1998). However, it is notable that iris Lisch nodules are
While NF1-associated astrocytomas are typically be- also melanocytic lesions. Finally, bone dyplasia affect-
nign, they can occasionally progress to high grade gli- ing the skull and face of some NF1 patients also appears
oblastomas. Nf11/2 mice do not develop these lesions; to originate from defects in neural crest–derived cranio-
however, mice carrying Nf1 and p53 mutations in cis facial bones.
can develop astrocytomas, of varying grades, with high Phenotypes in Nf1-deficent mice also suggest a func-
frequency. In 3 out of 5 tumors analyzed, LOH was ob- tion for neurofibromin in both neural crest–derived and
served at both loci supporting the role of neurofibromin adjacent non-neural-crest-derived cells. Nf12/2 embryos
inactivation and implicating p53 in this process as well die at midgestation (at approximately E14) due to a heart
(Reilly et al., 2000). Interestingly, tumor development defect known as double outlet right ventricle (DORV)
appears to be highly dependent on the genetic back- (Brannan et al., 1994; Jacks et al., 1994). This defect is
ground of these mice. Therefore, this model may be thought to result from improper rotation and septation
useful in probing the potential involvement of modifier of the outflow tract of the developing heart. Importantly,
loci in this phenotype. cardiac neural crest cells have been shown to contribute
to these tissues in vertebrates and have therefore been
suggested to underlie this defect (Epstein, 2000). How-Cognitive Deficits Associated with NF1
In addition to the tumorigenic symptoms, NF1 patients ever, Lakkis et al. have also observed endocardial cush-
ion hyperplasia, which was attributed to a defect in thecan also exhibit variable cognitive deficits (Upadhyaya
and Cooper, 1998). While some reports suggest a slight epithelial–mensenchymal transformation of cells within
the heart (Lakkis and Epstein, 1998). Thus, as in otherpredisposition to mental retardation, NF1 is more com-
monly associated with learning disabilities, which affect NF1-related phenotypes, both neural crest–derived and
non-neural-crest-derived cells may contribute to this30%–45% of patients. Magnetic resonance imaging has
shown that children with NF1 often exhibit UBOs (un- defect.
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Neurofibromin as a Ras-GAP either upstream or at the level of cyclase itself and/or
as a result of a negative feedback pathway. The docu-An important question that has arisen in the field is
whether neurofibromin truly functions as a Ras-GAP mented cooperativity of NF1 and GAP1 mutations in
flies also supports a Ras-GAP function. Still, the obser-protein and/or if this is its only function. As discussed
throughout this review, considerable data support a vations from NF1 mutant flies, coupled with the fact
that the GAP-related domain only comprises 10% of theRas-GAP function for neurofibromin in many cell types.
In addition to its sequence relatedness to known GAP neurofibromin protein, underscore the need for addi-
tional studies to dissect its function(s).proteins and the observation that it posseses GAP activ-
ity in vitro, Ras-GTP levels have been found to be ele-
vated in NF1-deficient tumor cell lines and primary cells. Regulation of Neurofibromin: A GAP
Furthermore, single point mutations, affecting Ras-GAP in Our Understanding
activity or Ras binding, have been detected in NF1 pa- While there remains uncertainty about which specific
tients, indicating that inactivation of this activity results pathways neurofibromin normally regulates, there is still
in the manifestation of the disease (Upadhyaya and Coo- less known about how the protein is normally regulated.
per, 1998). In addition, a subset of myeloid leukemias Boyer and collegues have found that nerofibromin be-
appear to arise as a result of either NF1 mutations or comes phosphorylated on serine and is redistributed in
N-Ras mutations, implying that deregulation of this path- response to IgM-crosslinking in B cells (Boyer et al.,
way is a critical step in their development (Upadhyaya 1994). However, phosphorylation or relocalization has
and Cooper, 1998). Finally, null Nf1 and GAP (p120GAP not been reported in any other cell type, nor has the
and GAP1, respectively) mutations result in more severe effect of this phosphorylation event on Ras-GAP activity
phenotypes in mice and flies, suggesting that these pro- been elucidated. Other groups have observed that spe-
teins do have overlapping or compensatory functions cific lipids inhibit neurofibromin’s GAP activity in vitro,
(Henkemeyer et al., 1995; The et al., 1997). Given this but the significance of these observations in vivo has
connection to the Ras pathway, efforts to utilize Ras not yet been determined. (Bollag and McCormick, 1991;
inhibitors to treat NF1 symptoms may prove to be an Han et al., 1991).
important therapeutic avenue.
Evidence for Haploinsufficiency: Why One Copy
May Not Be Good EnoughNeurofibromin May Not Exclusively Function
As discussed above, genetic analysis of human tumorsas a Ras-GAP
and mouse modeling studies have clearly indicated aThese data notwithstanding, there is reason to believe
role for complete loss of NF1 in the development of athat neurofibromin may not always or exclusively func-
number of NF1-related tumors. However, a mere reduc-tion as a Ras-GAP. While one class of Ras inhibitors,
tion in NF1 levels, due to the presence of one mutatedFTIs, suppress the proliferative defects of Nf1-deficent
allele, may underlie or contribute to many of the benignSchwann cells, they do not inhibit their angiogenic prop-
symptoms associated with the human disease (cogni-erties (Kim et al., 1997b). Furthermore, FTIs have been
tive deficits, bone deformations, cafe´-au-lait macules,shown to be ineffective in preventing or curing the mye-
Lisch nodules, and neurofibromas). Importantly, manyloproliferative disorder resulting from adoptive transfer
cell types examined and discussed throughout this re-of Nf12/2 hematopoietic cells into irradiated mice (Mah-
view exhibit haploinsufficiency for NF1 function in somegoub et al., 1999). While these particular agents may
cell culture assays. In vivo, haploinsufficiency has beennot effectively inhibit all Ras function in cells, another
recently addressed by Ingram and colleagues throughexplanation for these results is that some of the effects
effects on receptor signaling (Ingram et al., 2000). Aof NF1 mutations are mediated by other pathways. The
hypomorphic mutation in the c-kit receptor tyrosine ki-strongest evidence indicating a function of neurofi-
nase (W41) results in dramatic coat color defects andbromin other than Ras regulation has been suggested
reduced mast cell numbers in mice. Based on previousby Drosophila studies. Bernards, Guo, and coworkers
findings implicating neurofibromin in c-kit signalinghave found that flies harboring a mutant NF1 gene do
pathways in vitro, these investigators crossed Nf11/2not exhibit any of the phenotypes previously associated
animals with W41 mutant animals and found that hetero-with activated Ras but instead are small, exhibit a dimin-
zygosity at the Nf1 locus substatially rescued these de-ished escape response, and show defects in voltage-
fects. Thus, numerous observations indicate that lossgated potassium channel function and in learning and
of one NF1/Nf1 allele results in detectable biologicalshort-term memory (Guo et al., 1997, 2000; The et al.,
effects, perhaps through augmentation of Ras signaling1997). These phenotypes were not rescued by regulating
pathways. These observations may have implicationsRas1 signaling and instead were restored by an acti-
that extend beyond neurofibromatosis type 1, given thevated protein kinase A (PKA) transgene, implicating a
high mutational frequency of the NF1 gene.role for NF1 in the regulation of this pathway. These
reports also suggest that, in this system, NF1 appears
to act at or upstream of the rutabaga-encoded adenylyl Concluding Remarks
From the pleotropic symptoms exhibited by NF1 pa-cyclase.
However, while these data do suggest a convergence tients, the defects observed in mice carrying targeted
mutations in the Nf1 gene, and the cellular abnormalitiesof NF1 and the adenylyl cyclase pathway in flies, they
do not formally contradict the Ras-GAP function of neu- of Nf1-deficient cells, it is clear that neurofibromin func-
tion is critical in a wide variety of tissues and cell types.rofibromin. One possibility is that inappropriate Ras acti-
vation in NF1 mutant flies inhibits cyclase activation, Given the central role of Ras signaling pathways in so
Cell
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cytes induces a redistribution of neurofibromin but not p120-GAP.many biological processes, perhaps these observations
Oncogene 9, 349–357.are not so surprising. However, it is clear that loss of
Brannan, C.I., Perkins, A.S., Vogel, K.S., Ratner, N., Nordlund, M.L.,NF1 is not necessarily equivalent to an activating point
Reid, S.W., Buchberg, A.M., Jenkins, N.A., Parada, L.F., and Cope-mutation in the RAS gene. This may be due to a differ-
land, N.G. (1994). Targeted disruption of the neurofibromatosis
ence in the intensity or duration of Ras activation re- type-1 gene leads to developmental abnormalities in heart and vari-
sulting from NF1 versus Ras mutations and/or additional ous neural crest-derived tissues. Genes Dev. 8, 1019–1029.
functions of neurofibromin. In addition, the more subtle Bunge, M.B., Wood, P.M., Tynan, L.B., Bates, M.L., and Sanes, J.R.
activation of the Ras pathway resulting from NF1 muta- (1989). Perineurium originates from fibroblasts: demonstration in
vitro with a retroviral marker. Science 243, 229–231.tions may also be related to the observation that many
NF1 tumors are benign. However, while they are benign, Cardesa, A., Ribalta, T., Von Schilling, B., Palacin, A., and Mohr, U.
(1989). Experimental model of tumors associated with neurofibro-they are certainly complex in their etiology. In particular,
matosis. Cancer 63, 1737–1749.in the PNS and CNS, defects in multiple cell types appear
Cawthon, R.M., Weiss, R., Xu, G.F., Viskochil, D., Culver, M., Ste-to participate in their development. This complexity is
vens, J., Robertson, M., Dunn, D., Gesteland, R., O’Connell, P., etfurther compounded by potential cell-autonomous and
al. (1990). A major segment of the neurofibromatosis type 1 gene:
non-cell-autonomous effects, haploinsufficiency, and cDNA sequence, genomic structure, and point. Cell 62, 193–201.
the involvement of modifier genes. However, despite Cichowski, K., Shih, T.S., Schmitt, E., Santiago, S., Reilly, K.,
this complexity, in the ten years following the cloning McLaughlin, M.E., Bronson, R.T., and Jacks, T. (1999). Mouse mod-
of the NF1 gene, the field has made important progress els of tumor development in neurofibromatosis type 1. Science 286,
2172–2176.in elucidating the genetic events that underlie tumor
development and some of the basic cellular functions Colman, S.D., Williams, C.A., and Wallace, M.R. (1995). Benign neu-
rofibromas in type 1 neurofibromatosis (NF1) show somatic dele-of neurofibromin. The challenge for the future will be to
tions of the NF1 gene. Nat. Genet. 11, 90–92.expand and integrate these findings into a more com-
Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. (2000).plete understanding of how neurofibromin normally
MMP-9 supplied by bone marrow-derived cells contributes to skinfunctions in growth control and development.
carcinogenesis. Cell 103, 481–490.
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